Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temelimab SAD study in healthy volunteers
NCT02452996Phase 1Completed
- Sponsor
- GeNeuro
- Start
- Apr 2015
- Primary completion
- Aug 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of temelimab in multiple sclerosis (MS) (3 arms), sponsored by GeNeuro. Primary endpoint: Safety and tolerability of single ascending doses of GNbAC1 at 57 days. Started Apr 2015; status: completed.
02
Drugs
temelimab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02452996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02452996.